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NFAT promotes carcinoma invasive migration through glypican-6
Gary K. YIU, Aura KAUNISTO, Y. Rebecca CHIN and Alex TOKER1
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, U.S.A.
Invasive migration of carcinoma cells is a prerequisite for
the metastatic dissemination of solid tumours. Numerous
mechanisms control the ability of cancer cells to acquire a motile
and invasive phenotype, and subsequently degrade and invade the
basementmembrane.Severalgenesthatareup-regulatedinbreast
carcinoma are responsible for mediating the metastatic cascade.
Recent studies have revealed that the NFAT (nuclear factor of
activated T-cells) is a transcription factor that is highly expressed
in aggressive breast cancer cells and tissues, and mediates
invasion through transcriptional induction of pro-invasion and
migration genes. In the present paper we demonstrate that NFAT
promotes breast carcinoma invasion through induction of GPC
(glypican) 6, a cell-surface glycoprotein. NFAT transcriptionally
regulates GPC6 induction in breast cancer cells and binds
to three regulatory elements in the GPC6 proximal promoter.
Expression of GPC6 in response to NFAT signalling promotes
invasive migration, whereas GPC6 silencing with shRNA (small-
hairpin RNA) potently blocks this phenotype. The mechanism by
which GPC6 promotes invasive migration involves inhibition of
canonicalβ-cateninandWntsignalling,andup-regulationofnon-
canonical Wnt5A signalling leading to the activation of JNK (c-
JunN-terminalkinase)andp38MAPK(mitogen-activatedprotein
kinase). Thus GPC6 is a novel NFAT target gene in breast cancer
cells that promotes invasive migration through Wnt5A signalling.
Keywords:breastcancer,cancerinvasion,glypican,nuclearfactor
of activated T-cells (NFAT), transcription factor.
INTRODUCTION
NFAT (nuclear factor of activated T-cells) was originally
identiﬁed in immune cells as a transcription factor required
for the inducible expression of cytokines critical for triggering
the immune response [1,2]. Previous studies have revealed that
NFAT is ubiquitously expressed and regulates a plethora of
transcriptionalresponsesimportantforcellsurvival,angiogenesis
and cell growth in all cells and tissues [2,3]. Four distinct NFAT
family members, NFAT1, NFAT2, NFAT3 and NFAT4, bear
considerable sequence similarity and are calcium-responsive [4].
The more distantly related NFAT5 isoform is calcium-insensitive
[1]. The mechanisms of NFAT activation comprise one of the best
understood calcium-sensitive signalling mechanisms. In resting
cells, NFAT is sequestered in a hyperphosphorylated inactive
conformationinthecytoplasmand,uponstimulationwithligands
that elicit sustained elevation of intracellular calcium, NFAT is
dephosphorylatedbytheserine/threoninephosphatasecalcineurin
andtranslocatestothenucleus[5].AcycleofNFATrelocalization
to the cytoplasm is mediated by nuclear export kinases including
CK1 (casein kinase 1), GSK3 (glycogen synthase kinase 3) and
DYRKs (dual-speciﬁcity tyrosine-phosphorylated and -regulated
kinases) [1]. Classical NFATs typically interact with other
transcriptionfactorssuchasAP-1(activatorprotein-1)andGATA
proteins to activate transcription [4].
A recent study has demonstrated a role for NFAT signalling
in tumorigenesis [3]. Various NFAT isoforms promote cell
growth and cellular survival. Isoform-speciﬁc functions for
N F A T sa r el i k e l yt oe x i s ta sN F A T 1a p p e a r st of u n c t i o na sa
tumour suppressor, whereas NFAT2 has oncogenic activity [6].
Tumour angiogenesis is a key determinant in the progression of
human solid tumours leading to growth, invasive and metastatic
dissemination of tumour cells [7,8]. Previous studies have
demonstrated a key function for NFAT in both development and
tumour angiogenesis. A role for NFAT signalling in angiogenesis
is best illustrated in patients with Down’s syndrome who have
a lower incidence of tumour incidence. One explanation for this
ﬁnding is the increased expression of DSCR1 (Down’s syndrome
critical region 1) and DYRK1A that negatively regulate NFAT
activity and terminate NFAT-dependent gene transcription [9,10].
NFAT signalling also promotes the invasive migration of
tumour cells. Both NFAT1 and NFAT5 promote the migration
and invasion of breast and colon cancer cells [11]. NFATs
probably function to modulate invasion through the induction of
promotility and invasion genes. Autotaxin, also known as ENPP2
(exonucloeotide pyrophosphatase and phosphodiesterase 2), an
enzyme that catalyses the synthesis of LPA (lysophosphatidic
acid), is transcriptionally induced by NFAT in breast cancer
cells and promotes invasion [12]. Transgenic mice harbouring
autotaxininthemammaryepitheliumhaveincreasedfrequencyof
invasive and metastatic carcinoma [13]. Similarly, NFAT induces
the transcription of the COX2 (cyclo-oxygenase-2) gene in
cancer cells thereby enhancing invasive migration [14]. COX-2 is
responsible for the synthesis of PGE2 (prostaglandin E2), a potent
pro-invasionfactor.ThusNFATsignallingintumourcellsinduces
a transcriptional programme of genes that includes factors that
promote invasive migration leading to metastatic dissemination.
In the present paper we identify a novel target of NFAT, GPC
(glypican) 6, that modulates breast cancer cell invasive migration
acting through non-canonical Wnt5a signalling.
Abbreviations used: AP-1, activator protein-1; COX-2, cyclo-oxygenase-2; dox, doxycycline; DYRK, dual-speciﬁcity tyrosine-phosphorylated
and -regulated kinase; EGF, epidermal growth factor; EMSA, electrophoretic mobility-shift assay; ENPP2, exonucloeotide pyrophosphatase and
phosphodiesterase 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPC, glypican; JNK, c-Jun N-terminal kinase; HA, haemagglutinin; LPA,
lysophosphatidic acid; MAPK, mitogen-activated protein kinase; NFAT, nuclear factor of activated T-cells; PEI, polyethyleimine; PGE2, prostaglandin E2;
RT, reverse transcription; shRNA, small-hairpin RNA; siRNA, small interfering RNA; TCF, T-cell factor.
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Figure 1 Activation of NFAT1 enhances GPC6 expression and invasive migration
(A) Total RNA extracted from control or dox-treated SUM.N1#16 cells assayed for NFAT and GPC6 expression by RT-PCR. (B) Protein extracts from untreated cells or cells stimulated with dox
(1 μg/ml) with or without PMA/ ionomycin (ION) (100nM) immunoblotted with anti-HA, anti-GPC6 or anti-actin antibodies. (C) MDA-MB-231 cells transfected with empty vector (HA) or HA–GPC6
andassayedforTranswellmigrationandMatrigelinvasion.GPC6expressionwasconﬁrmedbyimmunoblottingwithanti-HAantibodies.(D)MigrationandMatrigelinvasionofHA–GPC6-transfected
SUM-159PT cells. HA–GPC6 expression was revealed by immunoblotting with anti-HA antibody. Results are means+ −S.D. of triplicate measurements for at least two independent experiments.
*P < 0.05 and #P < 0.01 between the control and transfected cells using an unpaired Student’s t test.
EXPERIMENTAL
Cell culture
The human cancer cell lines MDA-MB-231, MCF-7 and HeLa
were maintained in DMEM (Dulbecco’s modiﬁed Eagle’s
medium) with 1 g/ml glucose, L-glutamine and sodium pyruvate
(Mediatech) supplemented with 10% fetal bovine serum (Nova-
Tech). The oestrogen-independent breast cancer cell line SUM-
159PT was grown in Ham’s F-12 medium with L-glutamine
(Cambrex) supplemented with 5% fetal bovine serum, 1 μg/ml
hydrocortisone and 5 μg/ml insulin (Sigma–Aldrich). The
SUM.N1#16breastcancercellswithinducibleNFAT1expression
havebeendescribedpreviously[14]andweregrownintheculture
medium for SUM-159PT cells with of 20 μg/ml blasticidin
and 0.1 mg/ml zeocin (Invivogen). Cell lines were veriﬁed by
multiple methods including DNA barcoding, gene expression
and transcriptome analysis, and were kept in culture for less
than 6 months after receipt. Expression of NFAT1 was induced
with 1 μg/ml dox (doxycycline; Clontech) for 16–24 h at 37◦C.
For NFAT1 activation, breast cancer cells were treated with
50–100 nM PMA (Alexis Biochemicals) and ionomycin (EMD
Chemicals) for 16–20 h.
Plasmids
The HA (haemagglutinin)–NFAT expression vector has been
described previously [14]. The complete coding sequence of
human GPC6 in pREP4 (glyp6-pREP4) and the human genomic
PAC clone 1177C17 that contains the GPC6 promoter were
provided by Dr Guido David (VIB Department of Molecular and
Developmental Genetics, Leuven, Belgium) [15]. HA–GPC6 was
constructed by ﬁrst cloning an in-frame HA epitope tag between
the signal sequence and the coding region of GPC6. The HA-
taggedGPC6wasthensubclonedintopcDNA3.ThehumanGPC6
proximal promoter from −551 to +2 was prepared by PCR
using PAC 1177C17 as DNA template, with forward primer (5
 -
GTCGCTCGAGTGATTTCTGATCGAAGGC-3
 ) and reverse
primer(5
 -GCTGATAAGCTTGGAGACAGTCACTGGAGG-3
 ).
The ampliﬁed DNA was inserted into the XhoI/HindIII sites
of the promoter-less luciferase reporter plasmid pGL3-basic
(Promega) to generate Pr-551. Other GPC6 promoter constructs
were similarly prepared using Pr-551 as a template. To delete
the NFAT and AP-1 sites in Pr-551, speciﬁc PCR primer pairs
with matching restriction enzyme sites at the 5
 -ends were used.
After ampliﬁcation using Pr-551 as a template, the open ends of
c   The Authors Journal compilation c   2011 Biochemical Society © 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.NFAT induces GPC6 and promotes carcinoma invasion 159
Figure 2 Silencing GPC6 expression reduces invasive migration
SUM-159PT (A) and MDA-MB-231 (B) cells transfected with GPC6-speciﬁc shRNA in pLKO and assayed for migration and Matrigel invasion. GPC6 silencing by shRNA was conﬁrmed by
immunoblotting. Results are means+ −S.D. of triplicate measurements for at least two independent experiments. *P < 0.05 and #P < 0.01 between the control and transfected cells using an
unpaired Student’s t test. (C) SUM.N1#16 cells transfected with empty knockdown vector pLKO or GPC6-speciﬁc shRNA#1. Invasion of the transfected cells in Matrigel was determined in vitro with
orwithoutaddingdoxto induceexogenousNFATexpression.Resultsaremeans+ −S.D.oftriplicatemeasurementsforatleasttwoindependentexperiments.*P < 0.05betweenthe cells transfected
with pLKO or GPC6 shRNA in pLKO, with or without adding dox using an unpaired Student’s t test. NFAT activation and GPC6 silencing were conﬁrmed by immunoblotting.
the PCR fragments obtained were digested with the appropriate
restriction enzymes and ligated. The triple mutant construct was
similarly generated by PCR using the mutant Pr-551 plasmid as
a DNA template. Sequences of all constructs were conﬁrmed by
DNA sequencing.
GPC6 shRNA (small-hairpin RNA) was generated by cloning
the annealed oligonucleotides into the EcoRI/AgeI site of the
pLKO.1-puro lentiviral vector. The sequences of the oligonucleo-
tides were: shRNA#1, 5
 -CCGGAAGCCAGATACTTGCCTGA-
GACTCGAGTCTCAGGCAAGTATCTGGCTTTTTTTG-3
  and
5
 -AATTCAAAAAAAGCCAGATACTTGCCTGAGACTCGA-
GTCTCAGGCAAGTATCTGGCTT-3
 ;shRNA#2,5
 -CCGGAA-
TCTGTCCTCAGGAATATACCTCGAGGTATATTCCTGAGG-
ACAGATTTTTTTG-3
  and 5
 -AATTCAAAAAAATCTGTCC-
TCAGGAATATACCTCGAGGTATATTCCTGAGGACAGATT-
3
 ; and shRNA#4, 5
 -CCGGGCACAGCAAAGCCAGATACTT-
CTCGAGAAGTATCTGGCTTTGCTGTGCTTTTTG-3
  and
5
 -AATTCAAAAAGCACAGCAAAGCCAGATACTTCTCGA-
GAAGTATCTGGCTTTGCTGTGC-3
 . Wnt5A (S14873) and
Wnt5B(S37481)siRNAs(smallinterferingRNAs)wereobtained
from Applied Biosystems. The tetracycline-regulated pLKO
shRNA vector has been described previously [16], and was
used to generate tet-pLKO NFAT1 shRNA, based on sequences
published previously [14].
Immunoblotting
Cell lysates were prepared for immunoblotting as described
previously [14]. The anti-HA antibody was puriﬁed in-house
from the 12CA5 hybridoma. Anti-β-actin antibody was from
Sigma–Aldrich. Monoclonal anti-GPC6 antibody was
from LifeSpan BioSciences. Antibodies speciﬁc to Wnt5A/B,
total Akt, and phospho-Akt (Ser
473) were from Santa Cruz
Biotechnology. Antibodies speciﬁc against JNK (c-Jun N-
terminal kinase), phospho-JNK, p38 MAPK (mitogen-activated
proteinkinase)andphospho-p38MAPKwerefromCellSignaling
Technology.
Real-time RT (reverse transcription)–PCR
Total RNA extracted from cultured cells using TRIzol®
(Invitrogen) was reverse-transcribed into cDNA using Taqman
reverse transcriptase and oligo(dT)16 (Roche). Quantitative real-
timePCRwasperformedinanABIPrism7700sequencedetector
using SYBR Green PCR master mix (Applied Biosystems). The
PCR consists of a polymerase-activating step of 95◦C for 10 min,
followed by 40 cycles of a two-step cycling programme (95◦C
for 15 s; 60◦C for 1 min) for the detection of NFAT1, GPC6
and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) or a
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Figure 3 NFAT regulates the transcription of GPC6
(A) Nucleotide sequence of the human GPC6 putative promoter region from −551 to +2. The transcriptional start site is indicated by an arrow and is assigned +1. The potential NFAT-binding
sites are double underlined and putative AP-1 sites are single underlined. The numbers indicate the positions of the cis-regulatory elements relative to the transcriptional start site. (B) Schematic
representation of the GPC6 deletion constructs. The ﬁlled boxes and stippled boxes represent putative NFAT- and AP-1-binding sites respectively. The results of luciferase assays are depicted on
theright.(C)SchematicrepresentationofalterationsinthehumanGPC6promoterregionfrom −551to +2.DeletionsoftheNFAT-andAP-1-putativebindingsitesaredenotedbyopenboxesinthe
respective mutant constructs. Luciferase signals from the various constructs are shown on the right. Results are means+ −S.D. of triplicate measurements for at least two independent experiments.
*P < 0.05 and #P < 0.01 between the Pr-551 and the promoter construct being examined using an unpaired Student’s t test.
three-step cycling program (95◦C for 15 s; 56◦C for 30 s; 72◦C
for 45 s) Wnt5A. For NFAT1, the primers were 5
 -CGGAGTCC-
AAGGTTGTGTTCA-3
  (forward) and 5
 -TGTGGCTGACTT-
CGTTTCCTC-3
  (reverse). For GPC6, the primers were 5
 -CC-
TCTTGGGGCTGCTGCTC-3
  (forward) and 5
 -GTTCCC-
CTGCGATCTCCTGGTAG-3
  (reverse). For Wnt5A, the primers
were 5
 -AATAACCCTGTTCAGATGTCA-3
  (forward) and
5
 -TACTGCATGTGGTCCTGATA-3
  (reverse).ForGAPDH,the
primers were 5
 -GCAAATTCCATGGCACCGT-3
  (forward) and
5
 -TCGCCCCACTTGATTTTGG-3
  (reverse).
Transfection and lentiviral shRNA infection
All cell lines except MDA-MB-231 were transfected using
PEI (polyethyleimine) from Polysciences. Cells were 80–90%
conﬂuent at the time of transfection and were washed three times
with sterile PBS. PEI and DNA in the ratio of 3:1 (PEI/DNA)
in OptiMEM medium (Invitrogen) were vortex-mixed for 10 s
and incubated at room temperature (20◦C) for 15 min. The DNA
complexes formed were added to the cells in growth medium and
incubated for 3–4 h at 37◦C. The transfection solution was then
replaced with fresh growth medium and the cells were grown
at 37◦C overnight before being harvested for protein lysates,
RNA or luciferase assays. MDA-MB-231 cells were transfected
using Lipofectamine
TM 2000 (Invitrogen). Lentiviruses for gene
silencing experiments were prepared as described previously
[14].
Luciferase assays
Luciferase assays were performed using Promega’s luciferase
assay system as described previously [14]. The TOPﬂash TCF
(T-cell factor) reporter plasmid and S37A mutant β-catenin were
from Upstate Biotechnology.
EMSA (electrophoretic mobility-shift assay)
Nuclear protein extracts from untreated or dox-treated
SUM.N1#16 cells were prepared using homogenization and
high-salt buffer as described previously [17]. Doubled-stranded
oligonucleotides were labelled with biotin-11-dUTP using the
Biotin 3
  End DNA Labeling Kit from Pierce. Nuclear extracts
(5–10 μg) were pre-incubated on ice for 30 min in a binding
buffer containing 10 mM Tris/HCl (pH 7.5), 50 mM NaCl,
0.5 mM EDTA, 5% glycerol and 1μg of poly(dI-dC)·(dI-dC).
The protein–DNA complexes were resolved on native PAGE
(4% gel) in 0.5×TBE (22.5 mM Tris/borate and 0.5 mM EDTA,
pH 8.5) at 4◦C, and transferred on to Hybond-N
+ membranes
(Amersham). For competition mobility-shift or supershift assays,
nuclear extracts were pre-incubated with unlabelled competitor
oligonucleotides (100-fold molar excess) or antibodies (2 μg)
prior to addition of biotinylated probes. The sequences of the
sense strands of the double-stranded oligonucleotides used in
the present study were as follows: NFAT, 5
 -GATCTAAGGA-
GGAAAAACTGTTTCATGGATC-3
 ; G507, 5
 -GATCTAAG-
GGGAAATTGTTGAGTCTAGAACC-3
 ; G354, 5
 -CTATGA-
CTATTTCCACTCTGGCTTTGTGTTTCAGTAGG-3
 ; G141,
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Figure 4 NFAT directly binds to the GPC6 proximal promoter
OligonucleotidescontainingNFAT-andAP-1-bindingsitesintheIL(interleukin)-2(A)andGPC6(B)promoterwithaNFATsiteat −354andanAP-1siteat −337,incubatedwithnuclearextracts
from SUM.N1#16 cells. DNA–protein complexes were resolved and detected by chemiluminescence. Nuclear extracts (NX) used were from untreated (UT) or dox–treated cells. Molar excesses
(100-fold) of unlabelled double-stranded oligonucleotides as indicated at the top of the lanes were used as competitors. – signiﬁes no added competitor; NFAT, NFAT-AP1 sites in the IL-2 promoter;
G507,GPC6probewithanNFATsiteat −507andanAP-1siteat−498;G354,GPC6probewithanNFATsiteat −354andanAP-1siteat −337;G141,GPC6probewithanNFATsiteat −141;
κE2, immunoglobulin κ chain enhancer E box; Sp1, consensus sequence of the transcription factor SP1. The bracket at the left of the blot indicates the protein–DNA complexes formed by NFAT.
The arrow at the right-hand side denotes non-speciﬁc binding (NS). (C) Biotinylated oligonucleotide probes indicated at the bottom incubated with nuclear extracts from dox-treated SUM.N1#16
cells in the presence of non-immune IgG or antibodies speciﬁc against NFAT1 or HA. – signiﬁes no IgG or antibody; IgG, 2μg of non-immune IgG; α-NFAT, 2 μg of NFAT1 polyclonal antibody;
α-HA, 2μg of monoclonal HA antibody. The brackets at the left-hand side of the blots indicate the NFAT–DNA complexes, whereas the arrowheads on the right-hand side denote the supershifted
DNA–protein complexes.
5
 -CTTTTTCTTTTTTTCCCCTTTCTACCGCATAGGAAGA-
GA-3
 ;a n dκE2, 5
 -GATCAAGGCAGGTGGCCCAGATC-3
 .
The double-stranded transcription factor SP1 (speciﬁcity protein
1) consensus oligonucleotide was purchased from Promega. The
anti-NFAT1 antibodies and mouse non-immune IgG used in
supershift experiments were from Santa Cruz Biotechnology and
Jackson ImmunoResearch Laboratories respectively.
Migration and invasion assay
The assays were performed using Transwell chambers with 8 μm
pore ﬁlters (Corning) as described previously [14]. For migra-
tion assays, the cells were incubated at 37◦C for 1–3 h. For
invasion assays, the ﬁlters were coated with 5–10 μg Matrigel
(BDBiosciences)andthecellswereallowedtoinvadefor3–20 h.
RESULTS
Activation of NFAT stimulates GPC6 expression and promotes
invasive migration
To identify and characterize NFAT target genes that promote
carcinomacellinvasivemigration,wepreviouslygeneratedSUM-
159PT breast cancer cells that inducibly express NFAT1 upon
stimulation with dox [14]. Examination of expression proﬁles by
cDNA microarray analysis performed previously revealed that in
additiontoCOX2[14],GPC6isadistinctgeneinducedbyNFAT1
activation. Transcriptional induction of NFAT was concomitant
with a 3-fold induction of GPC6 in SUM.N1#16 cells treated
with dox (Figure 1A). Increased GPC6 protein expression was
also observed in cells stimulated with PMA and ionomycin to
activateNFAT(Figure1B).ThusGPC6isinducedinbreastcancer
cells in an NFAT1-dependent manner.
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SinceNFATisapro-migrationandinvasiontranscriptionfactor
[11], we next sought to determine whether GPC6 induction by
NFAT1contributestothesephenotypes.ExpressionofHA-tagged
GPC6 signiﬁcantly enhanced both migration and invasion of
MDA-MB-231andSUM-159-PTcells,comparedwiththecontrol
(Figures 1C and 1D). To conﬁrm the functional role of GPC6 in
modulating invasive migration, shRNA was used. Two distinct
GPC6 shRNAs quantitatively silenced GPC6 expression comp-
ared with the control and signiﬁcantly reduced cell migration and
invasion of SUM-159-PT and MDA-MB-231 cells (Figures 2A
and 2B). To provide a cause-and-effect demonstration that
induction of GPC6 by NFAT1 promotes invasion, GPC6 shRNA
was introduced into SUM.N1#16 cells followed by induction of
NFATbydox.InducibleexpressionofNFAT1stimulatesinvasion
as expected, and this was reduced to control levels in the presence
of GPC6 shRNA (Figure 2C). Therefore GPC6 is one factor that
contributes to the pro-invasion activity of NFAT.
NFAT regulates GPC6 transcription
To determine whether GPC6 is a direct NFAT target gene we
performed analysis of the GPC6 promoter. The NFAT minimal
consensus sequence is GGAAA(A) or TGGAAAGT. NFAT
also typically transactivates genes in co-operation with the AP-
1( fos/jun) complex. The AP-1 minimal consensus binding
sequence is TGASTCA, where S is either a cytosine or guanine.
Typically NFAT- and AP-1-binding sites are separated by seven
or less nucleotides. Analysis of the GPC6 proximal promoter
revealed several NFAT- and AP-1-binding sites upstream of the
transcriptional start site (Figure 3A). A series of 5
 -deletion
mutantsoftheGPC6promotersubclonedupstreamofaluciferase
reporter gene were transfected into SUM-159PT revealing that
transcription was signiﬁcantly reduced by deletion of the NFAT-
and AP-1-binding sites at −507 and −498 (Figure 3B, right-
hand panel). A further reduction in activity was observed by
deletion of the NFAT site at −354, but no difference was
seen between Pr-343 and Pr-127. Multiple luciferase reporter
constructs were also used in which the NFAT sites and/or AP-1
sites were replaced by unrelated sequences (Figure 3C, left-hand
panel). Removal of the NFAT (−507) and AP-1 (−498) sites
signiﬁcantly reduced luciferase activity compared with the intact
promoter (Figure 3C, right-hand panel). Interestingly, a more
signiﬁcant reduction in reporter activity was observed when the
NFAT site at −354 was replaced. The most signiﬁcant reduction
in luciferase activity was observed with Pr-551 triple mutant
construct, in which all the three NFAT sites are mutated.
To determine whether NFAT directly binds to the GPC6
promoter,EMSAswereperformed.Anoligonucleotideprobethat
contains a NFAT/AP-1 composite binding site that binds NFAT
proteins in Jurkat T-cells was used [18]. No detectable DNA–
proteincomplexwasdetectedwhenthisprobewasincubatedwith
nuclear proteins from untreated cells, probably due to low levels
of endogenous nuclear NFAT (Figure 4A, lane 2). In contrast,
multiple bands were detected when the probes were allowed to
bindtonuclearextractsfromdox-treatedcells(Figure4A,lane3).
Thesecomplexesarecompetedbytheadditionofa100-foldmolar
excessofunlabelledprobe(Figure4A,lane4)oroligonucleotides
that contain the NFAT sites in the GPC6 promoter (Figure 4A,
lanes 5–7). No competition was observed by adding equivalent
amounts of non-speciﬁc competitors (Figure 4A, lanes 8 and 9).
To investigate whether similar protein–DNA interactions were
detected with GPC6 probes, a probe (G354) that contains the
NFAT site (−354) and AP-1 site (−337) in the GPC6 promoter
was used. Several protein–DNA complexes were detected with
Figure 5 GPC6 and NFAT1 inhibit canonical Wnt/β-catenin signalling
(A) SUM 159-PT cells transiently transfected with TOPﬂash and S37A mutant β-catenin, HA,
GPC6 or NFAT1 plasmids, along with pCS2-(n)-βgal to control for transfection efﬁciency.
Luciferase activities were determined 24h after transfection. (B) Mutant S37A β-catenin
transiently transfected with increasing amounts of GPC6. Luciferase activities from TOPﬂash
were determined 24h after transfection. (C) Similar to (B), except plasmids encoding NFAT1
were used. Results are means+ −S.D. of triplicate measurements for at least two independent
experiments. #P < 0.01 in luciferase activities between the S37A and HA, GPC6 and NFAT1
plasmids,betweenHAcontrolandGPC6plasmids,andbetweenHAcontrolandNFAT1plasmids
as indicated by the brackets (unpaired Student’s t test).
nuclear extracts from dox-treated cells, but not untreated cells
(Figure 4B, compare lanes 2 and 3). These complexes have a
similar electrophoretic mobility as the complexes formed with
the NFAT probe (Figure 4A). Again binding was conﬁrmed using
speciﬁc (Figure 4B, lanes 4–7) and non-speciﬁc (Figure 4B, lanes
8and9)competitors.Moreover,NFATwaspresentintheseDNA–
proteincomplexes,sinceasupershiftwasobservedinthepresence
of the NFAT antibody (Figure 4C, left-hand panel, lane 3),
comparedwithirrelevantIgG(Figure4C,left-handpanel,lane2).
DNA–protein complexes were also detected with the GPC6 G507
probe from dox-treated SUM.N1#16 cells and were supershifted
with anti-NFAT1 or -HA antibodies (Figure 4C, middle panel,
lanes 4 and 5). Finally, using a biotinylated GPC6 G354 probe,
NFAT binding activity was also observed by a supershift in the
presence of NFAT1 or HA antibodies, but not non-immune IgG
(Figure4C,right-handpanel).Insummary,NFAT1inducesGPC6
expression by direct binding to several elements on the
GPC6 proximal promoter.
GPC6 and NFAT1 inhibit Wnt/β-catenin and activate Wnt5A
signalling
We next evaluated the mechanism by which the NFAT1/GPC6
signalling axis promotes breast cancer cell invasive migration.
We focused on Wnt signalling because Wnt proteins are involved
in controlling cell migration and are frequently deregulated in
humansolidtumours.StudieshavealsoshownthatGPCsregulate
metastasis by modulating Wnt [19,20]. A TOPﬂash reporter
plasmid, which contains two sets of three copies of the TCF-
binding site upstream of a TK (thymidine kinase) minimal
promoter and a luciferase open reading frame was used to
examine the TCF/β-catenin signalling in SUM-159PT cells [21].
A constitutively active S37A β-catenin mutant served as positive
control.RobustTOPﬂashactivitywasdetectedincellsexpressing
S37A β-catenin (Figure 5A). Conversely, cells expressing
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Figure 6 Activation of NFAT induces Wnt5A signalling through GPC6
(A) Lysates prepared from the indicated cell lines with or without overnight incubation with PMA and ionomycin, immunoblotted with anti-GPC6, anti-Wnt5A/B or anti-actin antibodies. (B)
MDA-MB-231stablepoolsharbouringcontroltet-pLKOorNFAT1shRNAwereinducedwithdox(100nM)for72handlysatesimmunoblottedwithanti-NFAT1,anti-GPC6,anti-Wnt5A/Boranti-actin
antibodies. (C) MDA-MB-231 or SUM-159PT cells transiently transfected with empty vector (HA) or HA–GPC6. Lysates were immunoblotted with anti-GPC6, anti-Wnt5A/B or anti-actin antibodies.
(D)SUM159-PTcellstransientlytransfectedwithemptyvectorcontrolorHA–GPC6,togetherwithcontrolsiRNAorWnt5A/BsiRNA,thenassayedformigration.HA–GPC6expressionandWnt5A/B
silencing were conﬁrmed by immunoblotting. (E) SUM-159-PT cells transiently transfected with either scrambled siRNA or Wnt5A/B siRNA were left unstimulated or stimulated with PMA and
ionomycin (100nM) and assayed for migration in Transwell assays. A portion of the lysates were immunoblotted with anti-Wnt5A/B or anti-actin antibodies. #P < 0.05 (unpaired Student’s t test).
All experiments are representative of at least three independent experiments.
exogenous GPC6 or NFAT1 showed signiﬁcantly reduced
luciferase activity compared with the control cells, indicating
GPC6 and NFAT1 inhibit the association of β-catenin with
the TCF transcription factors to form transcriptionally active
complexes that bind to Wnt target genes. Consistent with this,
TOPﬂash activity induced by S37A β-catenin was signiﬁcantly
diminished by expression of increasing amounts of GPC6
(Figure 5B) or NFAT1 (Figure 5C). These results indicate that
NFAT1 and GPC6 inhibit canonical Wnt signalling.
Although certain GPCs inhibit canonical Wnt/β-catenin
signalling, they can also enhance non-canonical Wnt [20,22].
Importantly, non-canonical Wnt5A promotes cell migration and
invasion [23,24]. To determine whether NFAT1 and GPC6
promote cancer cell invasive migration through non-canonical
Wnt5A signalling, we evaluated the induction of Wnt5A by
NFAT1 and GPC6. Increased GPC6 expression was detected
in two distinct breast cancer cell lines treated with PMA
and ionomycin to activate endogenous NFAT, along with a
concomitant increase in Wnt5A/B expression (Figure 6A).
In addition, inducible silencing of NFAT1 using tetracycline-
regulated shRNA (tet-pLKO) led to a signiﬁcant reduction in
GPC6 expression that was concomitant with reduced Wnt5A/B
levels (Figure 6B). Moreover, expression of exogenous GPC6 in
MDA-MB-231 and SUM-159PT cells led to increased Wnt5A/B
expression (Figure 6C). This increase was not due to enhanced
transcription as revealed by quantitative RT–PCR with primers
speciﬁc for Wnt5A and GPC6 (Supplementary Figure S1A at
http://www.BiochemJ.org/bj/440/bj4400157add.htm). Moreover,
enhancedmigrationinducedbyGPC6expressionwascompletely
blocked by Wnt5A/B siRNA (Figure 6D). Consistent with this,
induction of NFAT by doxycycline in SUM.N1#16 led to up-
regulation of Wnt5A/B protein levels (Supplementary Figure S2
at http://www.BiochemJ.org/bj/440/bj4400157add.htm). Finally,
stimulation of SUM-159-PT with PMA and ionomycin increased
cellmigrationandthiswascompletelyblockedincellstransduced
with Wnt5A/B siRNA (Figure 6E). Collectively, these results
provide a cause-and-effect demonstration that non-canonical
Wnt5 signalling is at least one mechanism by which the
NFAT/GPC6 signalling axis promotes cell motility.
GPC6 activates JNK and p38 MAPK
Finally, to investigate the signalling mechanisms that function
downstream of GPC6 and Wnt5A, we examined the activation
of JNK and p38 MAPK, which known to be activated by
Wnt5A [25]. Quantitative silencing of GPC6 using shRNA
(Figure7A)attenuatedEGF(epidermalgrowthfactor)-stimulated
JNK (Figure 7B) and p38 MAPK phosphorylation (Figure 7C).
This reduction in JNK and p38 MAPK activation was not due to a
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Figure 7 GPC6 regulates JNK and p38 MAPK signalling
(A–C) SUM-159-PT cells infected with GPC6 shRNA #1 or control empty vector pLKO,
serum-starved and then stimulated with EGF for 20min, and analysed by immunoblotting
with anti-GPC6 (A), anti-phospho-JNK (p-JNK) and total JNK (B), anti-phospho-p38 MAPK
(pMAPKp38)andtotalp38MAPK(C)antibodies.(D)SUM-159PTcellstransfectedwithvector
(HA)orHA–GPC6,serumstarvedandthenstimulatedwithEGFfor20min,andlysatesanalysed
by immunoblotting for phospho-Akt (pSer473) (pAkt) or total Akt. Anti-actin antibody served as
control in all cases. Results are representative of at least three independent experiments.
global non-speciﬁc reduction of signalling pathways, since GPC6
shRNA does not attenuate EGF-stimulated Akt phosphorylation
(Figure 7D).
DISCUSSION
Although NFAT was originally identiﬁed as a transcription
factor that mediates the immune response, it is now evident
that NFAT isoforms function as key transcriptional regulators
in all cells and tissues [5]. Functions ranging from heart valve
development, myogenesis, angiogenesis, cartilage formation and
neuronal development have all been ascribed to NFAT [1,2]. In
addition, a recent study has pointed to a role for NFAT in the
regulation of various phenotypes associated with tumorigenesis,
including cell growth, survival, endothelial cell signalling and
angiogenesis [3]. Our previous studies demonstrated that NFATs
are expressed in breast cancer cells and tissues from patients with
invasive breast carcinoma, and that NFAT activation promotes
invasive migration [11]. To date, two NFAT target genes, COX-2
and autotaxin (ENPP2), have been shown to promote cancer
cell invasive migration through the production of PGE2 and LPA
respectively [12,14]. In the present study, we identify GPC6 as
an NFAT-induced gene that also promotes invasive migration.
GPC6isamemberoftheGPCfamilyofHSPGs(heparinsulfate
proteoglycans) [26]. Using both pharmacological, genetic and
shRNA approaches we demonstrate that GPC6 is a direct NFAT-
target gene in breast cancer cells, and that NFAT directly binds to
the GPC6 promoter and thereby stimulates transcription. In turn,
increasedGPC6expressionenhancesinvasivemigrationinvitroin
amannerthatrequiresWnt5Asignalling.GPC6appearstobeboth
necessary and sufﬁcient at promoting invasive migration, since
exogenousexpressionenhancesandGPC6shRNAdecreasesboth
migration and invasion through Matrigel.
A role for GPCs in various phenotypes associated with
tumorigenesis is increasingly evident, although the results to date
have not provided a unifying model. Studies have shown that
GPCs can either potentiate or inhibit growth factor signalling.
GPC1 is expressed in breast carcinoma, glioma and pancreatic
cancer cells [27–29]. Loss of GPC1 reduces growth, metastasis
and tumorigenicity [30,31], and enhances FGF-2 (ﬁbroblast
growth factor-2) signalling [27,28]. In pancreatic cancer, GPC1
is required for TGF-β (transforming growth factor-β) signalling
[31]. Increased GPC3 expression has also been detected in
thyroid cancer, hepatocellular carcinoma, melanoma, squamous
cell carcinoma of the lungs, Wilms tumour and hepatoblastoma
[32–36]. Ectopic expression of GPC3 in breast cancer cells leads
to decreased growth and cell invasion, and enhances sensitivity
to apoptotic insults [37,38]. However, relatively little is known
concerning the expression or functional roles of GPC6 in human
solidtumoursandphenotypesassociatedwithcancerprogression.
Reduced expression or loss of function of GPC6 has recently
beendetectedinsporadicretinoblastomaandautosomal-recessive
omodysplasia [39,40]. To our knowledge, the present study is the
ﬁrst to identify a functional role for NFAT and GPC6 signalling
in carcinoma invasive migration.
GPCs regulate a variety of intracellular signalling mechanisms
and, depending on the cellular context, can either stimulate
or inhibit signalling. For example, GPC3 inhibits Hedgehog
signalling by competing with Patched for Hedgehog binding
[41]. In contrast, GPC3 stimulates Wnt by enhancing and/or
stabilizingtheinteractionofWntproteinsandtheirreceptors[19].
Since non-canonical Wnt signalling has been shown to promote
cell migration in an NFAT-dependent manner [42], we evaluated
whether GPC6-mediated invasive migration is dependent on
Wnt5A. We show that increased GPC6 expression induced by
NFAT enhances Wnt5A protein in the three distinct breast cancer
cell lines examined, reminiscent of studies showing that GPC3
inhibits canonical Wnt signalling in a manner that depends on
the activation of non-canonical Wnt [20,22]. The present study
points to Wnt5a functioning downstream of NFAT and GPC6 in
modulating invasive migration in breast cancer cells. In a separate
study, Wnt5a has been shown to also promote breast cancer cell
migration, but in an NFAT-dependent manner, suggesting that
Wnt5a may also function upstream and be required for efﬁcient
NFAT activation [42]. These opposing observations imply that
Wnt5a and NFAT are dependent on each other for efﬁcient signal
relay, such that perturbation in one or the other protein results in
inhibitionofbreastcancerphenotypessuchasinvasivemigration.
The precise mechanisms by which Wnt5a leads to NFAT
activation and in turn how Wnt5a activity is modulated by
NFAT remain to be determined.
Increased Wnt5A expression has been detected in melanoma,
pancreatic cancer, breast cancer and gastric cancer [24,43,44].
Although we detected expression of Wnt5A in various breast
cancercelllinesofdistinctorigin,itispresentlyunknownwhether
Wnt5A expression is increased in aggressive invasive and meta-
static carcinomas compared with normal epithelial cells and
tissues. Nonetheless, Wnt5A is known to enhance migration
and invasion, and studies have also shown that it enhances
proliferation and metastasis [23,24,43,45]. Clearly the
mechanisms by which Wnt5A promotes cancer progression will
depend on the cellular context and whether it functions in a cell-
autonomous manner or whether it also functions in the context
of the tumour microenvironment. Finally, we also show that
GPC6 induction of Wnt5A stimulates the activation of JNK and
p38 MAPK. This is reminiscent of GPC3, which also enhances
p38 MAPK and JNK activity [20,22]. Although the contribution
of either JNK or p38 MAPK to invasive migration in NFAT
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and GPC6 signalling is presently unknown, it is known that
JNK can be activated by Wnt5A to promote the migration and
invasion of breast epithelial and cancer cells [46–48]. Likewise,
non-canonical Wnt4A and Wnt5A are capable of activating p38
MAPK [49,50].
Insummary,wereport theidentiﬁcation ofanovel NFAT target
gene, GPC6, which functions to stimulate the invasive migration
ofbreastcancercells.SimilartoGPC3,GPC6probablyservesasa
coreceptortofacilitateand/orstabilizetheinteractionofWntsand
their receptors to stimulate non-canonical Wnt5A downstream.
This in turn will activate secondary downstream pathways that
are associated with promoting cell migration and invasion. These
observationsindicatethatNFATandGPC6modulatecellinvasion
through precisely controlled signalling loops and cross-talks with
other signalling pathways.
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Figure S1 Real-time quantitative PCR analysis of GPC6 or Wnt5a expression
MB-231(A)andSUM-159PT(B)cellstransientlytransfectedwithvector(HA)orHA–GPC6.Resultsaremeans+ −S.D.oftriplicatemeasurementsforatleasttwoindependentexperiments.#P <0.01
(unpaired Student’s t test).
Figure S2 Immunoblot analysis
Protein extracts from untreated SUM.N1#16 cells or cells stimulated with dox (1μg/ml) were
immunoblotted with anti-HA, anti-Wnt5A/B or anti-actin antibodies.
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